Shandong Science ›› 2025, Vol. 38 ›› Issue (1): 1-8.doi: 10.3976/j.issn.1002-4026.20240051

• Pharmacology and Toxicology •     Next Articles

Exploring the medication rule of Chrysanthemum morifolium Ramat. and investigating the synergistic pharmacological activity of core combination herbs

SUN Jingtian1,2,3(), LIU Feng1,2,3, ZHANG Zhe1, ZHANG Yufu4, MA Xinhui1,2,3, LI Qingjun1, WANG Xiao1,2,3, DONG Hongjing1,2,3,*()   

  1. 1. College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355
    2. Key Laboratory for Applied Technology of Sophisticated Analytical Instruments of Shandong Province, Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250014, China
    3. Key Laboratory for Natural Active Pharmaceutical Constituents Research in Universities of Shandong Province, College of Pharmacy, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250014, China
    4. Shandong Boda Medical Products Co.,Ltd., Heze 274300, China
  • Received:2024-04-03 Online:2025-02-20 Published:2025-01-21

RichHTML

PDF (PC)

Like

Abstract:

To explore the medication rule and pharmacological activity of the core combination of chrysanthemi flos,the drug frequency, complex network and association rules of Chrysanthemum prescriptions were analyzed. The network pharmacology research method was used to construct the "herbs-key target-disease" of core combination drugs. Combined with the forecast results, an in vitro cell model was used to evaluate the pharmacological effects of chrysanthemi flos drug combinations. A total of 92 prescriptions containing chrysanthemi flos were obtained, involving 212 herbs, and 32 herbs with frequency greater than or equal to 10.The association rules showed that the sustain and confidence degree of chrysanthemi flos-Glycyrrhizae radix et rhizoma were the highest, and chrysanthemi flos-glycyrrhizae radix et rhizoma-schizonepetae herba, chrysanthemi flos-glycyrrhizae radix et rhizoma-schizonepetae herba-chuanxiong rhizoma, chrysanthemi flos-glycyrrhizae radix et rhizome-schizonepetae herba-chuanxiong rhizome-saposhnikoviae radix were next to each other, respectively. Network pharmacology analysis showed that the core drug combination of chrysanthemi flos-glycyrrhizae radix et rhizoma could treat tumors, digestive system diseases, nervous system diseases and other diseases. In vitro cell activity study showed that the combination of chrysanthemi flos and glycyrrhizae radix et rhizoma had a better inhibition rate on NO levels than the single drug. Compared with the single use of chrysanthemi flos, the combination of drugs showed more significantactivity, reflecting the scientificity of compatibility of TCM in clinic.

Key words: flos of Chrysanthemum morifolium Ramat., data mining, medication rule, network pharmacology, biological validation

CLC Number: 

  • R285